Expression of Osteopontin in Oral Squamous Cell Carcinoma and its Surgical Margins-An Immunohistochemical Study

Dentistry Section

VIJAYA NIRMALA SUBRAMANI¹, MALATHI NARASIMHAN², MUTHUKUMAR THIYAGARAJAN³, BALU DAVID MUNUSWAMY⁴, LOG<u>ESWARI JAYAMANI⁵ _____</u>____

ABSTRACT

Introduction: Despite the advances in the treatment modalities offered for oral squamous cell carcinoma. The recurrence rate of it still remains quite high. Early detection of recurrence will improve the outcome and the survival of the patient. Osteopontin, a transformation-related phosphorylated protein in epithelial cells has been closely related with tumourigenesis. This study was undertaken to explore the potential of OPN as a tumour marker of recurrence in OSCC.

Aim: To analyse the expression of Osteopontin (OPN) in Oral Squamous Cell Carcinoma (OSCC), patient matched tumour free surgical margins and normal oral mucosa and to correlate with local & loco regional recurrence.

Materials and Methods: Twenty cases each of formalin fixed paraffin embedded blocks of histopathologically diagnosed cases of OSCC, patient matched tumour free surgical margins and

normal oral mucosal tissues were obtained from the archives of the Oral Pathology & Microbiology Department, Faculty of Dental Sciences, SRU and Govt. Arignar Anna Memorial Cancer Hospital, Kancheepuram. Immunohistochemical analysis was performed with an antibody to Osteopontin protein. Patients with secondary tumours and those treated with chemotherapy and radiotherapy were excluded from this study.

Results: The expression of OPN was elevated in 95% of tumours & 55% of histologically tumour free margin samples. There was negative OPN expression in normal mucosal samples. The result of the study was statistically analysed using Pearson chi-square test and was found to be statistically significant.

Conclusion: OPN can be used as a diagnostic marker in Oral Squamous Cell Carcinoma. In the tumour free surgical margins, elevated levels of OPN may predict a significantly increased risk of recurrence.

non specific background staining, the sections were treated with

peroxide block for 15 minutes at room temperature. After being

washed with water for 5 minutes, antigen retrieval was done by

pressure cooker method using citrate buffer solution at pH 6.0.

Sections were stained with Rabbit Monoclonal Osteopontin

Primary Antibody (ab91655 -EPR3688, Abcam, UK, 1:250) for

60 minutes at room temperature. After rinsing with Tris buffer

for 5 minutes, slides were incubated with secondary antibody

(ab80436, Abcam, UK) for 30 minutes at room temperature and

washed with Tris buffer twice. Finally the sections were incubated

with DAB- 3,3' diaminobenzidine and then rinsed in distilled water.

All slides were counter stained with haematoxylin for 1 minute,

washed in running water, dehydrated and mounted with DPX

- Dibutyl phathalate xylene. Haematoxylin and Eosin sections

of the representive cases were also prepared. Evaluation of

immunostaining was performed by a pathologist who was blinded with the clinical details. Human colon carcinoma was used as

a positive control for the IHC technique as per the instructions

provided in the Immuno Histo Chemistry test kit instruction

manual. The results of the study were statistically analysed by

Homogenous dark brown cytoplasmic & membranous staining

using Pearson chi-Square test.

study groups (Group II A & B).

RESULTS

Keywords: Immunohistochemistry, Surgical margins, Recurrence, Tumourogenesis

INTRODUCTION

Head & neck squamous cell carcinoma is the fifth most common malignant neoplasm which arises from diverse anatomical locations including oral cavity, oropharynx, larynx & hypopharynx [1]. In India cancer registries have confirmed a high evidence of oral cancer due to widespread habits of tobacco chewing, smoking and alcohol consumption [2]. Human papilloma virus has also been recently implicated in the aetiopathogenesis of OSCC [2,3]. The mutagenic effects of tobacco, alcohol, betel quid or areca-nut are dependent upon dose, frequency and duration of use, and are accelerated and exaggerated by the concurrent use of two or more of these agents [4]. Owing to the lack of the clinical symptoms in its early stages, the diagnosis of oral cancer still remains a challenging task [5]. The recurrence rate & metastasis of tumour is 30% even though the surgical margins are diagnosed as tumour free [6].

MATERIALS AND METHODS

A retrospective study was performed at the Department of Oral Pathology & Microbiology, Faculty of Dental Sciences, Sri Ramachandra University. The study samples consisted of 60 formalin fixed paraffin embedded biopsy specimens-20 Normal mucosa & 20 samples each of lesion and tumour free surgical margins from resected head and neck specimens. A tumour free surgical margin refers to the margins of the uninvolved tissue around the excised neoplasm which has been histopathologically confirmed.

The study samples were divided into:

- Group I Normal oral mucosa.
- Group II A Well differentiated Squamous cell carcinoma.

Group II B - Patient matched tumour free surgical margins.

A 5µm sections were cut and mounted on positively charged glass slides, deparaffinized with xylene and rehydrated in graded ethyl alcohol and water. To block endogenous peroxidase activity and

was taken as positive expression and significant OPN expression were observed in 95% (19/20) of Group II A [Table/Fig-1a-d] & 55% (11/20) of Group II B [Table/Fig-2a-I]. No OPN immunoreactivity was observed in Group I [Table/Fig-3a&b]. There were no significant differences among the various clinical parameters such as age, gender & site. A statistically highly significant difference in the expression of OPN was found between Group I, Group II A & II B (p-value=0.000) [Table/Fig-4a&b]. On the other hand, there was no statistically significant difference in expression of OPN in the intra



[Table/Fig-1a&b]: (a) Squamous cell carcinoma with epithelial pearls (H&E-40X), (b) Strong OPN expression in the dysplastic epithelium and squamous cell carcinoma islands in the connective tissue (IHC-20X)



[Table/Fig-1c&d]: (c) Intense staining of OPN in peripheral cells of squamous cell carcinoma island (IHC-40X), (c) Intense OPN cytoplasmic and membrane expressions (IHC-40X)



[Table/Fig-2a&b]: Positive OPN stain in epithelium in tumour free surgical margin (H&E, IHC-20X)



[Table/Fig-2c&d]: Positive staining of OPN in inflammatory cells and stromal cells in tumour free surgical margin (IHC-10X & 40X)



[Table/Fig-2e-g]: Lymph node with germinal center in tumour free surgical margin (H&E-10X, IHC-20X & 40X)



H&E -20X, IHC-20X & 40X)



[Table/Fig-2k&I]: Positive OPN expression – salivary glands in tumour free surgical margin (H&E, IHC-20X)



[Table/Fig-3a&b]: Study Control -Normal epithelium Showing Negative OPN expression (H&E- 20X, IHC-20X)



[Table/Fig-4a]: Graph Bar diagram depicting the distribution of the IHC OPN staining expression of the study samples (group I &IIA)



[Table/Fig-4b]: Graph Bar diagram depicting the distribution of the IHC OPN staining expression of the study samples (group I & IIB)

DISCUSSION

OPN, a secreted phosphorylated glycoprotein in the extracellular matrix was discovered by Senger et al., who defined it as a transformation related phosphorylated protein [7]. OPN is secreted by a variety of cells including osteoblasts, endothelial cells, epithelial cells, smooth muscle cells and macrophages. It is expressed in many kinds of cancers and has been associated with tumour cell growth, proliferation, invasion and metastatsis [8-12]. OPN promotes the development of malignancy by its stimulation of cellular transduction



[Table/Fig-5a&b]: Human Colon Carcinoma-Batch control (H&E-20X, IHC-10X)



[Table/Fig-5c]: Section shows Negative Batch control human colon carcinoma (IHC-20X)

pathways through $\alpha\nu\beta3$ [13]. Increased expression of the $\beta3$ integrin has been correlated with the increased invasiveness in melanoma lines [14]. Petrik et al., suggested plasma OPN is an independent prognostic marker for head & neck cancer [15]. Two studies have been carried so far, to evaluate the expression of OPN in human OSCC [16,17]. To the best of knowledge, this is the first study to analyse the expression of OPN in OSCC and patient matched tumour free surgical margins of OSCC.

In this study, human colon carcinoma sections were used as the IHC Test control [Table/Fig-5a-c]. There was a negative expression of OPN in all the 20 samples of normal oral mucosa [Table/Fig-3a&b]. A similar expression was also seen in the studies conducted by Devoll et al., & Zhou et al., [18,19]. In OSCC samples (group II A), 95% of cytoplasmic & membrane immunoreactivity was observed in the tumour islands [Table/Fig-1a-d]. These results were in accordance with the findings of Devoll et al., who reported significant percentage of OPN expression in cell lines derived from OSCC [18]. However, one case of OSCC in our study showed negative immunoreactivity for OPN. This may be attributed to lack of accessibility of antigen for its specific antibody as validated by Rudland et al., [20].

The present study showed significant difference in expression of OPN between the normal oral mucosa & patient matched tumour free surgical margins [Table/Fig-4b]. The tumour free surgical margins showed 55% positive expression in the epithelium, inflammatory cells & stromal cells [Table/Fig-2a-d]. Similar findings were described by Brown et al., & Masloub et al., who stated that the macrophage adjacent to tumour cells were likely the major source of OPN synthesis in the tumour environment [21,22]. Therefore immune staining of tumour cells and stromal cells for OPN protein were prominent at the invasive edge of the tumours.

Apart from the above mentioned findings, various significant observations were made. In the histological section of patient matched tumour free surgical margins, 3 out of 11 cases of lymph node showed positivity for OPN in the germinal centers [Table/Fig-2e-g]. Ito et al., reported an over-expression of OPN in lymph nodes by IHC and found it to be associated with a poor prognosis [23]. In the histological section of patient matched tumour free surgical margins 4 out of 11 cases of muscle tissues showed the OPN expression

[Table/Fig-2h-j]. Uaesoontrachoon et al., reported that myoblast cultures with fibroblast growth factor-2, transforming growth factor- β 1, interleukin 1-beta or thrombin showed significantly increased OPN expression [24]. These results suggested that myoblasts are an important source of OPN in damaged muscle. In salivary ductal cells of tumour free margin 3 out of 11 cases showed positivity for OPN [Table/Fig-2k,I]. Coppola et al., reported that in salivary gland carcinoma, the expression of OPN was minimal [25].

In our study, one patient who showed positive expression of OPN in tumour free surgical margins had recurrence after one year of follow up. Denhardt et al., stated that OPN produced by both tumour cells and stromal cells could enhance the metastatic capacity of tumour [26]. A role of OPN in facilitating the survival of the metastatic cell is suggested by the ability of OPN to suppress Nitrous oxide (NO) production. Nitrogen metabolites along with reactive oxygen species kill the circulating tumour cells by the phenomenon of oxidative burst of the macrophages. Since OPN causes the suppression of NO this can be directly correlated to the increased survival of the metastatic tumour cells. Rudland et al., suggested the presence of the metastasis associated protein OPN was tightly correlated with patient demise [20]. This could be applied to our case as well.

Various studies have shown that OPN supports attachment for a variety of cell types and promotes migration of tumours cells which has been also reaffirmed by the findings of our present study [27-29].

LIMITATION

We couldn't include the tongue cancer specimens as difficult to obtain tumor free surgical margin tissue from posterior margins of the tongue.

CONCLUSION

This study highlights that OPN can be used as a diagnostic biomarker in the OSCC. OPN expression in tumour free margins can be correlated to local recurrences and a relatively poor prognosis. Further long term studies with survival analyses can help in establishing as a potential prognostic of oral cancer.

REFERENCES

- Le QT, Sutphin PD, Raychaudhuri S, Yu SCT, et al. Identification of Osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. *Clinical Cancer Research*. 2003;9:59-67.
- [2] Feller L, Lemmer J. Oral squamous cell carcinoma: Epidemiology, clinical presentation and treatment. J cancer therapy. 2012;3:263-68.
- [3] Warnakulasuriya S. Prognostic and predictive markers for oral squamous cell carcinoma: The importance of clinical, pathological and molecular Markers. S J Medicine & Medical Sciences. 2014;2(1):12-16.
- [4] Scully C, Began J. Oral squamous cell carcinoma overview. J Oral Oncology. 2009;45:301-08.
- [5] Bree RD, Putten LVD, Brouwer J, Castelijns JA, et al. Detection of locoregional recurrent head and neck cancer after (chemo) radiotherapy using modern imaging. J Oral Oncology. 2009;45:301-08.
- [6] Blide A, Buchwald CV, Dabelsteen E, Therkildsenn MH, et al. Molecular markers in the surgical margin of oral carcinomas. J Oral Pathol Med. 2009;38:72-78.
- [7] Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. *Cell.* 1979;16:885-93.
- [8] Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic markers in ovarian cancer. J Biomed Sci. 2007;14(3):373-81.
- [9] Han WH, Wei WX, Can ET. Osteopontin expression in nasopharyngeal carcinoma: Its relevance to the clinical stage of the disease. J Cancer Research And Therapeutics. 2011;7(2):138-42.
- [10] Zhang LL, Shao SL, Wu Y. The expression and significance of Osteopontin and B7-H4 in epithelial ovarian neoplasm. *Chinese Journal of Cancer.* 2010;29(1):24-28.
- [11] Wu IC, Yang SF, Wu CC, Hsu WH, et al. Expression of osteopontin protein in esophageal squamous cell carcinoma. J Intern Med Taiwan. 2010;21:419-26.
- [12] Conti J, Thomas G. The role of tumour stroma in colorectal cancer invasion and metastasis. J Cancer. 2011;3:2160-68.
- [13] Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, et al. Osteopontin–a molecular for all seasons. *QJM: An Int J Med.* 2002;95(1)3-13.
- [14] Packer L, Pavey S, Parker A, Stark M, et al. Osteopontin is a downstream effector of the P13 kinase pathway in melanomas that is inversely correlated with functional PTEN. *Carcinogenesis*. 2006;27(9):1778-86.
- [15] Petrik D, Lavori PW, Cao H, Zhu Y, et al. Plasma Osteopontin Is an Independent prognostic marker for head and neck cancers. *Journal of Clinical Oncology*. 2006;24:5291-97.

- [16] Chien CY, Su CY, Chuang HC, Fang FM, et al. Clinical significance of osteopontin expression in T1 and T2 Tongue cancers. *Head & neck.* 2008;10:776-81.
- [17] Ogbureke KUE, Abdelsayed RA, Kushner H, Li Li BA, Fisher LW. Two members of the sibling family of proteins, dspp and bsp, may predict the transition of oral epithelial dysplasia to oral squamous cell carcinoma. *Cancer.* 2010;116(7):1709–17.
- [18] Devoll RE, Wei L, Woods KV, Pinero GP, et al. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. *J Oral Patho Med.* 1999;28:97-101.
- [19] Zhou ZT, Wei BJ, Shi P. Osteopontin expression in oral lichen planus. J Oral Pathol Med. 2008;37:94–98.
- [20] Rudland PS, Higgins AP, Tanani ME, Rudland SDS, et al. Prognostic Significance of the metastasis-associated protein osteopontin in human breast cancer. *Cancer Research*. 2002;62: 3417–27.
- [21] Brown LF, Sergiou AP, Berse B, Manseu EJ, et al. Osteopontin expression and distribution in human carcinomas. *American Journal of Pathology*.1994;145(3):610-23.
- [22] Masloub SM, Azim AMA, Elhamid ESA. CD10 & Osteopontin expression in dentigerous cyst and ameloblastoma. *Diagnostic pathology*, 2011;6:44.
- [23] Ito T, Hashimoto Y, Tanka E, Kan T, et al. An inducible short hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. *Clin Cancer Res.* 2006;12:1308-16.

- [24] Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, et al. Osteopontin and skeletal muscle myoblast :association with muscle regeneration and regulation of myoblast function in vitro. *The international J Biochemistry & Cell Biology*. 2008;10(40):2303-14.
- [25] Coppola D, Szabo M, Boulware D, Muraca P, et al. Correlation of Osteopontin protein expression and pathological stage across a wide variety of tumour Histologies. *Clinical Cancer Research*. 2002;10:184-90.
- [26] Denhardt DT, Noda M, Regan AWO, Pavlin D, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling and cell survival. *The Journal of Clinical Investigation*. 2001;107(9):1055-61.
- [27] Kim JH, Skates SJ, Uede T, Wong KK, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002;287:1671-79.
- [28] Chakraborty G, Jain S, Behera R, Ahmed M, et al. The multifaceted roles of osteopontin in cell signaling, tumour progression and angiogenesis. *Curr Mol Med*. 2006;6:819–30.
- [29] Rangaswami H, Bulbule A, Kundu GC. Osteopontin: Role in cell signaling and cancer progression. *Trends Cell Biol.* 2006;16:79–87.

PARTICULARS OF CONTRIBUTORS:

- 1. Senior Lecturer, Department of Oral Pathology and Microbiology, Faculty of Dental Sciences, Sri Ramachandra University, Chennai, India.
- 2. Professor and Head, Department of Oral Pathology and Microbiology, Faculty of Dental Sciences, Sri Ramachandra University, Chennai, India.
- 3. Associate Professor, Department of Anatomy, Sri Ramachandra University, Chennai, India.
- 4. Former Director, Government Arignar Anna Memorial Cancer Research Institute & Hospital, Kancheepuram, Tamilnadu, India.
- 5. Senior Lecturer, Department of Oral Pathology and Microbiology, Meenakshi Ammal Dental College, Tamilnadu, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Vijaya Nirmala Subramani,

No.17, Plot No:12/1,3rd Main Road, Lakshmi Nagar, Porur, Chennai-600116, Tamil Nadu, India. E-mail: subramani.viji3@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: Jan 02, 2015 Date of Peer Review: May 01, 2015 Date of Acceptance: Aug 19, 2015 Date of Publishing: Nov 01, 2015